Nykode Therapeutics AS reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 12.9 million compared to USD 7.17 million a year ago. Revenue was USD 13.32 million compared to USD 9.03 million a year ago.

Net loss was USD 35.15 million compared to USD 42.74 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.15 a year ago.